Clinical Trials Directory

Trials / Completed

CompletedNCT03596814

MOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE II

Retrospective and Descriptive Analysis of the Regimens of Treatment With FVIII, FIX and By-passing Agents for Hemophiliacs A or B With or Without Inhibitors, From the Existing Registry BERHLINGO, Before and After the Launch of New Entended Half-life Clotting Factors in Seven Haemophilia Treatment Centers in France

Status
Completed
Phase
Study type
Observational
Enrollment
2,072 (actual)
Sponsor
Nantes University Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

MOTHIF II is a non-interventional, multicenter, retrospective, observational data collection in seven French Haemophilia Treatment Centers of the BERHLINGO network. In the context of the arrival of new extended half-life products, the MOTHIF II study aims to describe the changes in therapeutic management of patients with hemophilia A \& B, following the provision of FVIII and FIX extended half-life factors in France; it will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.

Detailed description

Treatment regimens for haemophiliacs patients treated with clotting factors will be analysed globally for the patients of the two periods, by subgroup: * type of hemophilia: A or B * severity: severe, moderate, mild * history of inhibitors and then for each subgroup: * by regimen: 1) Prophylaxis 2) On demand 3) ITI * by type of clotting factors: FVIII or FIX or by-passing agents, plasma-derived or recombinant, standard or extended half-life clotting factors, INN Will also be included in the analyse: * demographic data: age (years) * clinical data: weight (kgs) if available * treatment data: regimen, consumptions (number of UI of clotting factors consumed on the period) and costs of clotting factors (€).

Conditions

Interventions

TypeNameDescription
OTHERNo Interventional studyRetrospective data

Timeline

Start date
2019-11-13
Primary completion
2019-12-31
Completion
2019-12-31
First posted
2018-07-24
Last updated
2020-05-18

Locations

7 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03596814. Inclusion in this directory is not an endorsement.